Skip to main content
S&P 5007,703.68+1.78%DOW53,353.36+3.03%NASDAQ25,840.70+1.85%BTC$80,191.00+3.38%ETH$2,421.42+5.73%GOLD$4,071.80+3.33%OIL$87.76-8.67%
Smart Investors Daily
SID Premium
AK

NASDAQ · AKBA

Akebia Therapeutics, Inc.

Healthcare · Biotechnology

$0.73

Down-$0.01 (-1.06%)

Updated Nov 4, 2026, 7:30 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
347.63M
P/E ratio
-65.04
Dividend yield
0.00%
52-week range
$0.54 – $2.23
Volume
6.18M
Avg. volume
3.34M

Price performance · AKBA

AKBA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

AKBA closed at $0.73 after 21 trading sessions, down 17.38% for the selected period.

Last close
$0.73
Period change
-17.38%
Period low
$0.56
Period high
$0.88
Daily close
View OHLC price history
AKBA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.7247$0.7474$0.705$0.72586.18M
Nov 2, 2026$0.71$0.73$0.692$0.70844.82M
Oct 30, 2026$0.721$0.7348$0.6951$0.70652.78M
Oct 29, 2026$0.7798$0.80$0.7365$0.74225.03M
Oct 28, 2026$0.674$0.7774$0.657$0.76466.96M
Oct 27, 2026$0.6367$0.6799$0.6345$0.66045.43M
Oct 26, 2026$0.5878$0.6754$0.5765$0.643811.59M
Oct 23, 2026$0.5662$0.5964$0.5622$0.566911M
Oct 22, 2026$0.5751$0.6044$0.5421$0.562213.1M
Oct 21, 2026$0.609$0.6402$0.571$0.585319.54M
Oct 20, 2026$0.68$0.7063$0.6116$0.61819.98M
Oct 19, 2026$0.674$0.7003$0.67$0.68017.76M
Oct 16, 2026$0.703$0.7337$0.6659$0.677.13M
Oct 15, 2026$0.7036$0.7249$0.69$0.69558.92M
Oct 14, 2026$0.7504$0.77$0.70$0.70213.96M
Oct 13, 2026$0.80$0.8049$0.7655$0.776.5M
Oct 12, 2026$0.80$0.8069$0.7717$0.79028.87M
Oct 9, 2026$0.8203$0.8324$0.8011$0.80116.09M
Oct 8, 2026$0.8521$0.8664$0.8148$0.81487.45M
Oct 7, 2026$0.8633$0.8874$0.8633$0.87349.16M
Oct 6, 2026$0.9015$0.909$0.875$0.87856.18M

Latest AKBA news

The latest Smart Investors Daily articles mentioning AKBA.

Stock researchCompany · Overview

AKBA research

Overview

Company profile and research snapshot.

Company profile

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.50
Implied upside
—
Analysts
—
AKBA recent ratings
DateFirmRatingTarget
Sep 15, 2026BTIGBuy—
Sep 8, 2026WestPark CapitalBuy—
Aug 7, 2026Leerink PartnersMarket Perform—
Jul 1, 2026HC Wainwright & Co.Buy—
Apr 7, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimenWALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, presented data from the Vafseo Outcom

Yahoo · Oct 7, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. During meetin

Yahoo · Oct 6, 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Additional poster presentations highlight Vafseo® (vadadustat) clinical and economic dataWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By